CB 2: A cannabinoid receptor with an identity crisis

British Journal of Pharmacology

Volumn 160, Issue 3, 2010, Pages 467-479

  Atwood, Brady K ^a,b   MacKie, Ken ^a  

^a INDIANA UNIVERSITY   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

GPCR tissue distribution; Immunocytochemistry; Microglia; Pain; Sensory neurons

Indexed keywords

1 (2,3 DICHLOROBENZOYL) 5 METHOXY 2 METHYL 3 (2 MORPHOLINOETHYL)INDOLE; 1 DEOXY 3 (1,1 DIMETHYLBUTYL) DELTA8 TETRAHYDROCANNABINOL; 2 METHYL 3 (1 NAPHTHOYL) 1 PROPYLINDOLE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 3 (2 IODO 5 NITROBENZOYL) 1 (1 METHYL 2 PIPERIDINYLMETHYL)INDOLE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; 6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; A 769260; A 796260; A 836339; CANNABINOID 2 RECEPTOR; CANNABINOID 2 RECEPTOR AGONIST; CANNABINOID 2 RECEPTOR ANTAGONIST; CANNABINOID RECEPTOR ANTAGONIST; DEXANABINOL; GW 8333972A; GW 833972A; NALOXONE; UNCLASSIFIED DRUG;

ANALGESIC ACTIVITY; ANTIEMETIC ACTIVITY; BINDING AFFINITY; BRAIN REGION; BRAIN STEM; CELL FUNCTION; CENTRAL NERVOUS SYSTEM; CEREBELLUM; DRUG ACTIVITY; DRUG BINDING; DRUG DOSAGE FORM COMPARISON; DRUG TARGETING; HIPPOCAMPUS; HUMAN; IMMUNE SYSTEM; IN SITU HYBRIDIZATION; INTESTINE INNERVATION; NERVE CELL; NERVOUS SYSTEM DEVELOPMENT; NOCICEPTION; NONHUMAN; PAIN ASSESSMENT; PERIPHERAL NERVOUS SYSTEM; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TISSUE DISTRIBUTION; ANIMAL; DRUG EFFECT; METABOLISM; PHYSIOLOGY;

ANIMALS; CENTRAL NERVOUS SYSTEM; HUMANS; IMMUNE SYSTEM; NEURONS; PERIPHERAL NERVOUS SYSTEM; RECEPTOR, CANNABINOID, CB2;

EID: 77952623444     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2010.00729.x     Document Type: Review

References (145)

1. Abbadie C, Bhangoo S, De Koninck Y, Malcangio M, Melik-Parsadaniantz S, White FA (2009). Chemokines and pain mechanisms. Brain Res Rev 60 : 125 134.
2. Adams IB, Martin BR (1996). Cannabis: pharmacology and toxicology in animals and humans. Addiction 91 : 1585 1614.
3. Alexander SP, Mathie A, Peters JA (2008). Guide to Receptors and Channels (GRAC), 3rd edition. Br J Pharmacol 153 : S1 209.
4. Anand U, Otto WR, Sanchez-Herrera D, Facer P, Yiangou Y, Korchev Y et al. (2008). Cannabinoid receptor CB2 localisation and agonist-mediated inhibition of capsaicin responses in human sensory neurons. Pain 138 : 667 680.
5. Anand P, Whiteside G, Fowler CJ, Hohmann AG (2009). Targeting CB2 receptors and the endocannabinoid system for the treatment of pain. Brain Res Rev 60 : 255 266.
6. Ashton JC, Friberg D, Darlington CL, Smith PF (2006). Expression of the cannabinoid CB2 receptor in the rat cerebellum: an immunohistochemical study. Neurosci Lett 396 : 113 116.
7. Ashton JC, Glass M (2007). The Cannabinoid CB2 Receptor as a Target for Inflammation-Dependent Neurodegeneration. Curr Neuropharmacol 5 : 73 80.
8. Ashton JC, Rahman RM, Nair SM, Sutherland BA, Glass M, Appleton I (2007). Cerebral hypoxia-ischemia and middle cerebral artery occlusion induce expression of the cannabinoid CB2 receptor in the brain. Neurosci Lett 412 : 114 117.
9. Baek JH, Zheng Y, Darlington CL, Smith PF (2008). Cannabinoid CB2 receptor expression in the rat brainstem cochlear and vestibular nuclei. Acta Otolaryngol 128 : 961 967.
10. Bayewitch M, Avidor-Reiss T, Levy R, Barg J, Mechoulam R, Vogel Z (1995). The peripheral cannabinoid receptor: adenylate cyclase inhibition and G protein coupling. FEBS Lett 375 : 143 147.
11. Beltramo M, Bernardini N, Bertorelli R, Campanella M, Nicolussi E, Fredduzzi S et al. (2006). CB2 receptor-mediated antihyperalgesia: possible direct involvement of neural mechanisms. Eur J Neurosci 23 : 1530 1538.
12. Belvisi MG, Patel HJ, Freund-Michel V, Hele DJ, Crispino N, Birrell MA (2008). Inhibitory activity of the novel CB2 receptor agonist, GW833972A, on guinea-pig and human sensory nerve function in the airways. Br J Pharmacol 155 : 547 557.
13. Benito C, Nunez E, Tolon RM, Carrier EJ, Rabano A, Hillard CJ et al. (2003). Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer's disease brains. J Neurosci 23 : 11136 11141.
14. Berdyshev EV (2000). Cannabinoid receptors and the regulation of immune response. Chem Phys Lipids 108 : 169 190.
15. Bingham B, Jones PG, Uveges AJ, Kotnis S, Lu P, Smith VA et al. (2007). Species-specific in vitro pharmacological effects of the cannabinoid receptor 2 (CB2) selective ligand AM1241 and its resolved enantiomers. Br J Pharmacol 151 : 1061 1070.
16. Bouaboula M, Desnoyer N, Carayon P, Combes T, Casellas P (1999a). Gi protein modulation induced by a selective inverse agonist for the peripheral cannabinoid receptor CB2: implication for intracellular signalization cross-regulation. Mol Pharmacol 55 : 473 480.
17. Bouaboula M, Dussossoy D, Casellas P (1999b). Regulation of peripheral cannabinoid receptor CB2 phosphorylation by the inverse agonist SR 144528. Implications for receptor biological responses. J Biol Chem 274 : 20397 20405.
18. Bouaboula M, Poinot-Chazel C, Marchand J, Canat X, Bourrie B, Rinaldi-Carmona M et al. (1996). Signaling pathway associated with stimulation of CB2 peripheral cannabinoid receptor. Involvement of both mitogen-activated protein kinase and induction of Krox-24 expression. Eur J Biochem 237 : 704 711.
19. Brown SM, Wager-Miller J, Mackie K (2002). Cloning and molecular characterization of the rat CB2 cannabinoid receptor. Biochim Biophys Acta 1576 : 255 264.
20. Brusco A, Tagliaferro P, Saez T, Onaivi ES (2008). Postsynaptic localization of CB2 cannabinoid receptors in the rat hippocampus. Synapse 62 : 944 949.
21. Buckley NE, McCoy KL, Mezey E, Bonner T, Zimmer A, Felder CC et al. (2000). Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB(2) receptor. Eur J Pharmacol 396 : 141 149.
22. Burdyga G, Lal S, Varro A, Dimaline R, Thompson DG, Dockray GJ (2004). Expression of cannabinoid CB1 receptors by vagal afferent neurons is inhibited by cholecystokinin. J Neurosci 24 : 2708 2715.
23. Bussolati G, Leonardo E (2008). Technical pitfalls potentially affecting diagnoses in immunohistochemistry. J Clin Pathol 61 : 1184 1192.
24. Cabral GA, Griffin-Thomas L (2009). Emerging role of the cannabinoid receptor CB2 in immune regulation: therapeutic prospects for neuroinflammation. Expert Rev Mol Med 11 : e3.
25. Cabral GA, Raborn ES, Griffin L, Dennis J, Marciano-Cabral F (2008). CB2 receptors in the brain: role in central immune function. Br J Pharmacol 153 : 240 251.
26. Calignano A, La Rana G, Giuffrida A, Piomelli D (1998). Control of pain initiation by endogenous cannabinoids. Nature 394 : 277 281.
27. Carayon P, Marchand J, Dussossoy D, Derocq JM, Jbilo O, Bord A et al. (1998). Modulation and functional involvement of CB2 peripheral cannabinoid receptors during B-cell differentiation. Blood 92 : 3605 3615.
28. Carlisle SJ, Marciano-Cabral F, Staab A, Ludwick C, Cabral GA (2002). Differential expression of the CB2 cannabinoid receptor by rodent macrophages and macrophage-like cells in relation to cell activation. Int Immunopharmacol 2 : 69 82.
29. Costa B (2007). On the pharmacological properties of Delta9- tetrahydrocannabinol (THC). Chem Biodivers 4 : 1664 1677.
30. Cullheim S, Thams S (2007). The microglial networks of the brain and their role in neuronal network plasticity after lesion. Brain Res Rev 55 : 89 96.
31. Derbenev AV, Stuart TC, Smith BN (2004). Cannabinoids suppress synaptic input to neurones of the rat dorsal motor nucleus of the vagus nerve. J Physiol 559 : 923 938.
32. Derocq JM, Segui M, Marchand J, Le Fur G, Casellas P (1995). Cannabinoids enhance human B-cell growth at low nanomolar concentrations. FEBS Lett 369 : 177 182.
33. Devane WA, Dysarz FA, 3rd., Johnson MR, Melvin LS, Howlett AC (1988). Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 34 : 605 613.
34. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G et al. (1992). Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258 : 1946 1949.
35. Dittel BN (2008). Direct suppression of autoreactive lymphocytes in the central nervous system via the CB2 receptor. Br J Pharmacol 153 : 271 276.
36. Duncan M, Mouihate A, Mackie K, Keenan CM, Buckley NE, Davison JS et al. (2008). Cannabinoid CB2 receptors in the enteric nervous system modulate gastrointestinal contractility in lipopolysaccharide-treated rats. Am J Physiol Gastrointest Liver Physiol 295 : G78 G87.
37. Elmes SJ, Jhaveri MD, Smart D, Kendall DA, Chapman V (2004). Cannabinoid CB2 receptor activation inhibits mechanically evoked responses of wide dynamic range dorsal horn neurons in naive rats and in rat models of inflammatory and neuropathic pain. Eur J Neurosci 20 : 2311 2320.
38. Felder CC, Briley EM, Axelrod J, Simpson JT, Mackie K, Devane WA (1993). Anandamide, an endogenous cannabimimetic eicosanoid, binds to the cloned human cannabinoid receptor and stimulates receptor-mediated signal transduction. Proc Natl Acad Sci U S A 90 : 7656 7660.
39. Felder CC, Joyce KE, Briley EM, Mansouri J, Mackie K, Blond O et al. (1995). Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol Pharmacol 48 : 443 450.
40. Fernandez-Ruiz J, Pazos MR, Garcia-Arencibia M, Sagredo O, Ramos JA (2008). Role of CB2 receptors in neuroprotective effects of cannabinoids. Mol Cell Endocrinol 286 : S91 S96.
41. Frey KA, Albin RL (2001). Receptor binding techniques. Curr Protoc Neurosci 14 : 1 14. Chapter 1: Unit1 4.
42. Galiegue S, Mary S, Marchand J, Dussossoy D, Carriere D, Carayon P et al. (1995). Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 232 : 54 61.
43. Gallant M, Dufresne C, Gareau Y, Guay D, Leblanc Y, Prasit P et al. (1996). New class of potent ligands for the human peripheral cannabinoid receptor. Bioorganic & Medicinal Chemistry Lett 6 : 2263 2268.
44. Goncalves MB, Suetterlin P, Yip P, Molina-Holgado F, Walker DJ, Oudin MJ et al. (2008). A diacylglycerol lipase-CB2 cannabinoid pathway regulates adult subventricular zone neurogenesis in an age-dependent manner. Mol Cell Neurosci 38 : 526 536.
45. Gong JP, Onaivi ES, Ishiguro H, Liu QR, Tagliaferro PA, Brusco A et al. (2006). Cannabinoid CB2 receptors: immunohistochemical localization in rat brain. Brain Res 1071 : 10 23. (Pubitemid 43255471)
46. Gonsiorek W, Lunn C, Fan X, Narula S, Lundell D, Hipkin RW (2000). Endocannabinoid 2-arachidonyl glycerol is a full agonist through human type 2 cannabinoid receptor: antagonism by anandamide. Mol Pharmacol 57 : 1045 1050.
47. Griffin G, Fernando SR, Ross RA, McKay NG, Ashford ML, Shire D et al. (1997). Evidence for the presence of CB2-like cannabinoid receptors on peripheral nerve terminals. Eur J Pharmacol 339 : 53 61.
48. Griffin G, Tao Q, Abood ME (2000). Cloning and pharmacological characterization of the rat CB(2) cannabinoid receptor. J Pharmacol Exp Ther 292 : 886 894.
49. Griffin G, Wray EJ, Tao Q, McAllister SD, Rorrer WK, Aung MM et al. (1999). Evaluation of the cannabinoid CB2 receptor-selective antagonist, SR144528: further evidence for cannabinoid CB2 receptor absence in the rat central nervous system. Eur J Pharmacol 377 : 117 125.
50. Grimaldi P, Orlando P, Di Siena S, Lolicato F, Petrosino S, Bisogno T et al. (2009). The endocannabinoid system and pivotal role of the CB2 receptor in mouse spermatogenesis. Proc Natl Acad Sci U S A 106 : 11131 11136.
51. Hanisch UK, Kettenmann H (2007). Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nat Neurosci 10 : 1387 1394.
52. Hanus L, Abu-Lafi S, Fride E, Breuer A, Vogel Z, Shalev DE et al. (2001). 2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc Natl Acad Sci U S A 98 : 3662 3665.
53. Hanus L, Breuer A, Tchilibon S, Shiloah S, Goldenberg D, Horowitz M et al. (1999). HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor. Proc Natl Acad Sci U S A 96 : 14228 14233.
54. He F, Song ZH (2007). Molecular and cellular changes induced by the activation of CB2 cannabinoid receptors in trabecular meshwork cells. Mol Vis 13 : 1348 1356.
55. Henstridge CM, Balenga NA, Ford LA, Ross RA, Waldhoer M, Irving AJ (2009). The GPR55 ligand L-alpha-lysophosphatidylinositol promotes RhoA-dependent Ca2+ signaling and NFAT activation. FASEB J 23 : 183 193.
56. Herkenham M, Lynn AB, Johnson MR, Melvin LS, de Costa BR, Rice KC (1991). Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci 11 : 563 583.
57. Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, de Costa BR et al. (1990). Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A 87 : 1932 1936.
58. Herrera B, Carracedo A, Diez-Zaera M, Gomez del Pulgar T, Guzman M, Velasco G (2006). The CB2 cannabinoid receptor signals apoptosis via ceramide-dependent activation of the mitochondrial intrinsic pathway. Exp Cell Res 312 : 2121 2131.
59. Herrera B, Carracedo A, Diez-Zaera M, Guzman M, Velasco G (2005). p38 MAPK is involved in CB2 receptor-induced apoptosis of human leukaemia cells. FEBS Lett 579 : 5084 5088.
60. Hillsley K, McCaul C, Aerssens J, Peeters PJ, Gijsen H, Moechars D et al. (2007). Activation of the cannabinoid 2 (CB2) receptor inhibits murine mesenteric afferent nerve activity. Neurogastroenterol Motil 19 : 769 777.
61. Hohmann AG, Herkenham M (1999a). Cannabinoid receptors undergo axonal flow in sensory nerves. Neuroscience 92 : 1171 1175.
62. Hohmann AG, Herkenham M (1999b). Localization of central cannabinoid CB1 receptor messenger RNA in neuronal subpopulations of rat dorsal root ganglia: a double-label in situ hybridization study. Neuroscience 90 : 923 931.
63. Howlett AC (2002). The cannabinoid receptors. Prostaglandins Other Lipid Mediat 68-69 : 619 631.
64. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA et al. (2002). International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 54 : 161 202.
65. Huffman JW, Liddle J, Yu S, Aung MM, Abood ME, Wiley JL et al. (1999). 3-(1',1'-Dimethylbutyl)-1-deoxy-delta8-THC and related compounds: synthesis of selective ligands for the CB2 receptor. Bioorg Med Chem 7 : 2905 2914.
66. Ibrahim MM, Deng H, Zvonok A, Cockayne DA, Kwan J, Mata HP et al. 2003). Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS. Proc Natl Acad Sci U S A 100 : 10529 10533.
67. Ibrahim MM, Porreca F, Lai J, Albrecht PJ, Rice FL, Khodorova A et al. 2005). CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids. Proc Natl Acad Sci U S A 102 : 3093 3098.
68. Ibrahim MM, Rude ML, Stagg NJ, Mata HP, Lai J, Vanderah TW et al. 2006). CB2 cannabinoid receptor mediation of antinociception. Pain 122 : 36 42.
69. Jhaveri MD, Elmes SJ, Richardson D, Barrett DA, Kendall DA, Mason R et al. (2008). Evidence for a novel functional role of cannabinoid CB(2) receptors in the thalamus of neuropathic rats. Eur J Neurosci 27 : 1722 1730.
70. Jiang S, Fu Y, Williams J, Wood J, Pandarinathan L, Avraham S et al. (2007). Expression and function of cannabinoid receptors CB1 and CB2 and their cognate cannabinoid ligands in murine embryonic stem cells. Plos One 2 : e641.
71. Julien B, Grenard P, Teixeira-Clerc F, Van Nhieu JT, Li L, Karsak M et al. (2005). Antifibrogenic role of the cannabinoid receptor CB2 in the liver. Gastroenterology 128 : 742 755.
72. Kapur A, Zhao P, Sharir H, Bai Y, Caron MG, Barak LS et al. (2009). Atypical responsiveness of the orphan receptor GPR55 to cannabinoid ligands. J Biol Chem 284 : 29817 29827.
73. Khanolkar AD, Lu D, Ibrahim M, Duclos RI, Jr., Thakur GA, Malan TP et al. (2007). Cannabilactones: a novel class of CB2 selective agonists with peripheral analgesic activity. J Med Chem 50 : 6493 6500.
74. Klegeris A, Bissonnette CJ, McGeer PL (2003). Reduction of human monocytic cell neurotoxicity and cytokine secretion by ligands of the cannabinoid-type CB2 receptor. Br J Pharmacol 139 : 775 786.
75. Kress M, Kuner R (2009). Mode of action of cannabinoids on nociceptive nerve endings. Exp Brain Res 196 : 79 88.
76. Lauckner JE, Jensen JB, Chen HY, Lu HC, Hille B, Mackie K (2008). GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. Proc Natl Acad Sci U S A 105 : 2699 2704.
77. Lion T (2001). Current recommendations for positive controls in RT-PCR assays. Leukemia 15 : 1033 1037.
78. Liu QR, Pan CH, Hishimoto A, Li CY, Xi ZX, Llorente-Berzal A et al. (2009). Species differences in cannabinoid receptor 2 (CNR2 gene): identification of novel human and rodent CB2 isoforms, differential tissue expression and regulation by cannabinoid receptor ligands. Genes Brain Behav 8 : 519 530.
79. Lorincz A, Nusser Z (2008). Specificity of immunoreactions: the importance of testing specificity in each method. J Neurosci 28 : 9083 9086.
80. Lu Q, Straiker A, Maguire G (2000). Expression of CB2 cannabinoid receptor mRNA in adult rat retina. Vis Neurosci 17 : 91 95.
81. Lynn AB, Herkenham M (1994). Localization of cannabinoid receptors and nonsaturable high-density cannabinoid binding sites in peripheral tissues of the rat: implications for receptor-mediated immune modulation by cannabinoids. J Pharmacol Exp Ther 268 : 1612 1623.
82. Maccarrone M (2008). CB2 receptors in reproduction. Br J Pharmacol 153 : 189 198.
83. Mackie K (2005). Distribution of cannabinoid receptors in the central and peripheral nervous system. Handb Exp Pharmacol 168 : 299 325.
84. Malan TP, Jr., Ibrahim MM, Deng H, Liu Q, Mata HP, Vanderah T et al. (2001). CB2 cannabinoid receptor-mediated peripheral antinociception. Pain 93 : 239 245.
85. Malan TP, Jr., Ibrahim MM, Lai J, Vanderah TW, Makriyannis A, Porreca F (2003). CB2 cannabinoid receptor agonists: pain relief without psychoactive effects? Curr Opin Pharmacol 3 : 62 67.
86. Maresz K, Pryce G, Ponomarev ED, Marsicano G, Croxford JL, Shriver LP et al. (2007). Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells. Nat Med 13 : 492 497.
87. Mathison R, Ho W, Pittman QJ, Davison JS, Sharkey KA (2004). Effects of cannabinoid receptor-2 activation on accelerated gastrointestinal transit in lipopolysaccharide-treated rats. Br J Pharmacol 142 : 1247 1254.
88. Matsuda LA, Bonner TI, Lolait SJ (1993). Localization of cannabinoid receptor mRNA in rat brain. J Comp Neurol 327 : 535 550.
89. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI (1990). Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346 : 561 564.
90. McCoy KL, Matveyeva M, Carlisle SJ, Cabral GA (1999). Cannabinoid inhibition of the processing of intact lysozyme by macrophages: evidence for CB2 receptor participation. J Pharmacol Exp Ther 289 : 1620 1625.
91. Miller AM, Stella N (2008). CB2 receptor-mediated migration of immune cells: it can go either way. Br J Pharmacol 153 : 299 308.
92. Molina-Holgado F, Rubio-Araiz A, Garcia-Ovejero D, Williams RJ, Moore JD, Arevalo-Martin A et al. (2007). CB2 cannabinoid receptors promote mouse neural stem cell proliferation. Eur J Neurosci 25 : 629 634.
93. Morgan NH, Stanford IM, Woodhall GL (2009). Functional CB2 type cannabinoid receptors at CNS synapses. Neuropharmacology 57 : 356 368.
94. Mukherjee S, Adams M, Whiteaker K, Daza A, Kage K, Cassar S et al. (2004). Species comparison and pharmacological characterization of rat and human CB2 cannabinoid receptors. Eur J Pharmacol 505 : 1 9.
95. Munro S, Thomas KL, Abu-Shaar M (1993). Molecular characterization of a peripheral receptor for cannabinoids. Nature 365 : 61 65.
96. Nackley AG, Zvonok AM, Makriyannis A, Hohmann AG (2004). Activation of cannabinoid CB2 receptors suppresses C-fiber responses and windup in spinal wide dynamic range neurons in the absence and presence of inflammation. J Neurophysiol 92 : 3562 3574.
97. Naguib M, Diaz P, Xu JJ, Astruc-Diaz F, Craig S, Vivas-Mejia P et al. (2008). MDA7: a novel selective agonist for CB2 receptors that prevents allodynia in rat neuropathic pain models. Br J Pharmacol 155 : 1104 1116.
98. Ofek O, Karsak M, Leclerc N, Fogel M, Frenkel B, Wright K et al. (2006). Peripheral cannabinoid receptor, CB2, regulates bone mass. Proc Natl Acad Sci U S A 103 : 696 701.
99. Ohta H, Ishizaka T, Tatsuzuki M, Yoshinaga M, Iida I, Yamaguchi T et al. (2008). Imine derivatives as new potent and selective CB2 cannabinoid receptor agonists with an analgesic action. Bioorg Med Chem 16 : 1111 1124.
100. Onaivi ES (2006). Neuropsychobiological evidence for the functional presence and expression of cannabinoid CB2 receptors in the brain. Neuropsychobiology 54 : 231 246.
101. Onaivi ES, Carpio O, Ishiguro H, Schanz N, Uhl GR, Benno R (2008a). Behavioral effects of CB2 cannabinoid receptor activation and its influence on food and alcohol consumption. Ann N Y Acad Sci 1139 : 426 433.
102. Onaivi ES, Ishiguro H, Gong JP, Patel S, Meozzi PA, Myers L et al. (2008b). Brain neuronal CB2 cannabinoid receptors in drug abuse and depression: from mice to human subjects. Plos One 3 : e1640.
103. Onaivi ES, Ishiguro H, Gong JP, Patel S, Perchuk A, Meozzi PA et al. (2006). Discovery of the presence and functional expression of cannabinoid CB2 receptors in brain. Ann N Y Acad Sci 1074 : 514 536.
104. Palazuelos J, Aguado T, Egia A, Mechoulam R, Guzman M, Galve-Roperh I (2006). Non-psychoactive CB2 cannabinoid agonists stimulate neural progenitor proliferation. FASEB J 20 : 2405 2407.
105. Patel HJ, Birrell MA, Crispino N, Hele DJ, Venkatesan P, Barnes PJ et al. (2003). Inhibition of guinea-pig and human sensory nerve activity and the cough reflex in guinea-pigs by cannabinoid (CB2) receptor activation. Br J Pharmacol 140 : 261 268.
106. Pertwee R, Griffin G, Fernando S, Li X, Hill A, Makriyannis A (1995). AM630, a competitive cannabinoid receptor antagonist. Life Sci 56 : 1949 1955.
107. Pietr M, Kozela E, Levy R, Rimmerman N, Lin YH, Stella N et al. (2009). Differential changes in GPR55 during microglial cell activation. FEBS Lett 583 : 2071 2076.
108. Price TJ, Helesic G, Parghi D, Hargreaves KM, Flores CM (2003). The neuronal distribution of cannabinoid receptor type 1 in the trigeminal ganglion of the rat. Neuroscience 120 : 155 162.
109. Price DA, Martinez AA, Seillier A, Koek W, Acosta Y, Fernandez E et al. (2009). WIN55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Eur J Neurosci 29 : 2177 2186.
110. Rinaldi-Carmona M, Barth F, Millan J, Derocq JM, Casellas P, Congy C et al. (1998). SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J Pharmacol Exp Ther 284 : 644 650.
111. Roche R, Hoareau L, Bes-Houtmann S, Gonthier MP, Laborde C, Baron JF et al. (2006). Presence of the cannabinoid receptors, CB1 and CB2, in human omental and subcutaneous adipocytes. Histochem Cell Biol 126 : 177 187.
112. Romero-Sandoval EA, Horvath R, Landry RP, DeLeo JA (2009). Cannabinoid receptor type 2 activation induces a microglial anti-inflammatory phenotype and reduces migration via MKP induction and ERK dephosphorylation. Mol Pain 5 : 25.
113. Ross RA, Brockie HC, Stevenson LA, Murphy VL, Templeton F, Makriyannis A et al. (1999). Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656, and AM630. Br J Pharmacol 126 : 665 672.
114. Ross RA, Coutts AA, McFarlane SM, Anavi-Goffer S, Irving AJ, Pertwee RG et al. (2001). Actions of cannabinoid receptor ligands on rat cultured sensory neurones: implications for antinociception. Neuropharmacology 40 : 221 232.
115. Ryberg E, Larsson N, Sjogren S, Hjorth S, Hermansson NO, Leonova J et al. (2007). The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 152 : 1092 1101.
116. Sagar DR, Kelly S, Millns PJ, O'Shaughnessey CT, Kendall DA, Chapman V (2005). Inhibitory effects of CB1 and CB2 receptor agonists on responses of DRG neurons and dorsal horn neurons in neuropathic rats. Eur J Neurosci 22 : 371 379.
117. Saper CB, Sawchenko PE (2003). Magic peptides, magic antibodies: guidelines for appropriate controls for immunohistochemistry. J Comp Neurol 465 : 161 163.
118. Schatz AR, Lee M, Condie RB, Pulaski JT, Kaminski NE (1997). Cannabinoid receptors CB1 and CB2: a characterization of expression and adenylate cyclase modulation within the immune system. Toxicol Appl Pharmacol 142 : 278 287.
119. Shire D, Calandra B, Rinaldi-Carmona M, Oustric D, Pessegue B, Bonnin-Cabanne O et al. (1996). Molecular cloning, expression and function of the murine CB2 peripheral cannabinoid receptor. Biochim Biophys Acta 1307 : 132 136.
120. Shmist YA, Goncharov I, Eichler M, Shneyvays V, Isaac A, Vogel Z et al. (2006). Delta-9-tetrahydrocannabinol protects cardiac cells from hypoxia via CB2 receptor activation and nitric oxide production. Mol Cell Biochem 283 : 75 83.
121. Shoemaker JL, Joseph BK, Ruckle MB, Mayeux PR, Prather PL (2005a). The endocannabinoid noladin ether acts as a full agonist at human CB2 cannabinoid receptors. J Pharmacol Exp Ther 314 : 868 875.
122. Shoemaker JL, Ruckle MB, Mayeux PR, Prather PL (2005b). Agonist-directed trafficking of response by endocannabinoids acting at CB2 receptors. J Pharmacol Exp Ther 315 : 828 838.
123. Showalter VM, Compton DR, Martin BR, Abood ME (1996). Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands. J Pharmacol Exp Ther 278 : 989 999.
124. Skaper SD, Buriani A, Dal Toso R, Petrelli L, Romanello S, Facci L et al. (1996). The ALIAmide palmitoylethanolamide and cannabinoids, but not anandamide, are protective in a delayed postglutamate paradigm of excitotoxic death in cerebellar granule neurons. Proc Natl Acad Sci U S A 93 : 3984 3989.
125. Slipetz DM, O'Neill GP, Favreau L, Dufresne C, Gallant M, Gareau Y et al. (1995). Activation of the human peripheral cannabinoid receptor results in inhibition of adenylyl cyclase. Mol Pharmacol 48 : 352 361.
126. Stander S, Schmelz M, Metze D, Luger T, Rukwied R (2005). Distribution of cannabinoid receptor 1 (CB1) and 2 (CB2) on sensory nerve fibers and adnexal structures in human skin. J Dermatol Sci 38 : 177 188.
127. Stella N (2004). Cannabinoid signaling in glial cells. Glia 48 : 267 277.
128. Storr M, Gaffal E, Saur D, Schusdziarra V, Allescher HD (2002). Effect of cannabinoids on neural transmission in rat gastric fundus. Can J Physiol Pharmacol 80 : 67 76. (Pubitemid 34194288)
129. Sugiura T, Kondo S, Kishimoto S, Miyashita T, Nakane S, Kodaka T et al. (2000). Evidence that 2-arachidonoylglycerol but not N-palmitoylethanolamine or anandamide is the physiological ligand for the cannabinoid CB2 receptor. Comparison of the agonistic activities of various cannabinoid receptor ligands in HL-60 cells. J Biol Chem 275 : 605 612.
130. Sugiura T, Kondo S, Sukagawa A, Nakane S, Shinoda A, Itoh K et al. (1995). 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun 215 : 89 97.
131. Suzuki T, Higgins PJ, Crawford DR (2000). Control selection for RNA quantitation. Biotechniques 29 : 332 337.
132. Urban JD, Clarke WP, von Zastrow M, Nichols DE, Kobilka B, Weinstein H et al. (2007). Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther 320 : 1 13.
133. Valenzano KJ, Tafesse L, Lee G, Harrison JE, Boulet JM, Gottshall SL et al. (2005). Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy. Neuropharmacology 48 : 658 672.
134. Van Sickle MD, Duncan M, Kingsley PJ, Mouihate A, Urbani P, Mackie K et al. (2005). Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 310 : 329 332.
135. Viscomi MT, Oddi S, Latini L, Pasquariello N, Florenzano F, Bernardi G et al. (2009). Selective CB2 receptor agonism protects central neurons from remote axotomy-induced apoptosis through the PI3K/Akt pathway. J Neurosci 29 : 4564 4570.
136. Walter L, Franklin A, Witting A, Wade C, Xie Y, Kunos G et al. (2003). Nonpsychotropic cannabinoid receptors regulate microglial cell migration. J Neurosci 23 : 1398 1405.
137. Whiteside GT, Lee GP, Valenzano KJ (2007). The role of the cannabinoid CB2 receptor in pain transmission and therapeutic potential of small molecule CB2 receptor agonists. Curr Med Chem 14 : 917 936.
138. Wotherspoon G, Fox A, McIntyre P, Colley S, Bevan S, Winter J (2005). Peripheral nerve injury induces cannabinoid receptor 2 protein expression in rat sensory neurons. Neuroscience 135 : 235 245.
139. Yao BB, Hsieh G, Daza AV, Fan Y, Grayson GK, Garrison TR et al. (2009). Characterization of a cannabinoid CB2 receptor-selective agonist, A-836339 [2,2,3,3-tetramethyl-cyclopropanecarboxylic acid [3-(2-methoxy-ethyl)-4,5- dimethyl-3H-thiazol-(2Z)-ylidene]-amide], using in vitro pharmacological assays, in vivo pain models, and pharmacological magnetic resonance imaging. J Pharmacol Exp Ther 328 : 141 151.
140. Yao BB, Hsieh GC, Frost JM, Fan Y, Garrison TR, Daza AV et al. (2008). In vitro and in vivo characterization of A-796260: a selective cannabinoid CB2 receptor agonist exhibiting analgesic activity in rodent pain models. Br J Pharmacol 153 : 390 401.
141. Yao BB, Mukherjee S, Fan Y, Garrison TR, Daza AV, Grayson GK et al. (2006). In vitro pharmacological characterization of AM1241: a protean agonist at the cannabinoid CB2 receptor? Br J Pharmacol 149 : 145 154.
142. Yiangou Y, Facer P, Durrenberger P, Chessell IP, Naylor A, Bountra C et al. (2006). COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord. BMC Neurol 6 : 12.
143. Zhang J, Hoffert C, Vu HK, Groblewski T, Ahmad S, O'Donnell D (2003). Induction of CB2 receptor expression in the rat spinal cord of neuropathic but not inflammatory chronic pain models. Eur J Neurosci 17 : 2750 2754.
144. Zhong L, Geng L, Njie Y, Feng W, Song ZH (2005). CB2 cannabinoid receptors in trabecular meshwork cells mediate JWH015-induced enhancement of aqueous humor outflow facility. Invest Ophthalmol Vis Sci 46 : 1988 1992.
145. Zoratti C, Kipmen-Korgun D, Osibow K, Malli R, Graier WF (2003). Anandamide initiates Ca(2+) signaling via CB2 receptor linked to phospholipase C in calf pulmonary endothelial cells. Br J Pharmacol 140 : 1351 1362.